Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix™, a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores).



from The Medical News http://ift.tt/1Emw4TD